On May 18, 2020, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Tecentriq (atezolizumab). This approval specifically pertained to the drug's efficacy, indicating an expansion or modification of its approved uses based on new data.
Background
Atezolizumab, marketed as Tecentriq, is an established therapeutic agent. The FDA's action on this date was a supplemental approval, which typically signifies an update or addition to an already approved drug's label. Supplemental applications can cover new indications, new patient populations, changes in dosing, or other modifications to the drug's prescribing information. In this instance, the approval was categorized specifically under "Efficacy," meaning the FDA reviewed and accepted new data supporting the drug's effectiveness for an expanded or altered use.
What this means
The supplemental efficacy approval for Tecentriq (atezolizumab) on May 18, 2020, signifies that the FDA has acknowledged new clinical data demonstrating the drug's effectiveness in an additional or modified context. While the specific details of the new indication or patient population are not provided in the available data, such approvals are crucial for expanding treatment options for patients. Clinicians should consult the updated prescribing information for Tecentriq to understand the precise scope of this new efficacy approval and its implications for patient care. This type of approval allows healthcare providers to utilize atezolizumab in a broader range of clinical scenarios where its efficacy has been scientifically validated and regulatory approved.
Source
The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA). Details can be found in the FDA's overview of supplemental applications for BLA 761034, with the specific event dated May 18, 2020, on accessdata.fda.gov.